JRC Publications Repository

JRC Publications Repository >

Browsing by Author MOLINET Roger

Sort by: In order: Results/Page Authors/Record:
Showing results 1 to 19 of 19
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2000Alpha-Emitting Bismuth Cyclohexybenzyl DTPA Constructs of Recombinant Humanized Anti-CD33 Antibodies: Pharmacokinetics, Bioactivity, Toxicity and Chemistry.NIKULA T.; MC DEVITT M.r.; WU Ch.; KOZAK R.w.; GARMESTANI K.; BRECHBIEL M.w.; CURCIO M.j.; PIPPIN C.g.; TIFFANI-JONES L.; GEERLINGS, SR. M.w., et alArticles in Journals
2001Cancer Treatment Using Bi-213 and Ac-225 in Radioimmunotherapy.APOSTOLIDIS Christos; CARLOS-MARQUEZ R.; JANSSENS Willem; MOLINET Roger; NIKULA T.; QUADI AliArticles in Journals
2005Cyclotron Production of Ac-225 for Targeted Alpha TherapyAPOSTOLIDIS CHRISTOS; MOLINET Roger; MCGINLEY JOHN; ABBAS KAMEL; MOELLENBECK J.; MORGENSTERN ALFREDArticles in Journals
2005Cyclotron Production of Ac-225 for Targeted Alpha TherapyAPOSTOLIDIS CHRISTOS; MOLINET Roger; MCGINLEY JOHN; MOELLENBECK J.; MORGENSTERN ALFRED; ABBAS KAMELArticles in Journals
2005Cyclotron Production of Ac-225 for Targeted Alpha Therapy.APOSTOLIDIS Christos; MOLINET Roger; MC GINLEY J.; MOELLENBECK J.; MORGENSTERN A.Articles in Journals
2005Cyclotron Production of Ac-225 for Targeted alpha Therapy.APOSTOLIDIS Christos; MOLINET Roger; MC GINLEY J.; ABBAS Kamel; MOLLENBECK J.Articles in Journals
1998Development and Validation of a Simple, Rapid and Robust Method for the Chemical Separation of Uranium and Plutonium.APOSTOLIDIS Christos; MOLINET Roger; RICHIR P.; OUGIER Michel charles g; MAYER KlausArticles in Journals
2000High-Linear Energy Transfer (LET) alpha vs Low-LET beta Emitters in Radioimmunotherapy of Solid Tumors: Therapeutic Efficacy and Dose-Limiting Toxicity of 213Bi- vs 90Y-Labeled CO17-1A Fab' Fragments in a Human Colonic Cancer Model.BEHR T.m.; BEHE M.; STABIN M.g.; WEHRMANN E.; APOSTOLIDIS Christos; MOLINET Roger; STRUTZ F.; FAYYAZI A.; WIELAND E.; GRATZ S.t., et alArticles in Journals
2003In Vitro Evaluation of 231Bi-Rituximab versus External Gamma Irradiation for the Treatment of B-CLL Patients: Relative Biological Efficacy with Respect to Apoptosis Induction and Chromosomal Damage.VANDENBULCKE K.; DE VOS F.; OFFNER Fritz; PHILIPPE Jan; APOSTOLIDIS Christos; MOLINET Roger; NIKULA T.k.; BACHER K.; DE GELDER V.; VRAL A., et alArticles in Journals
2001Lysine Protection against Bismuth Accumulation in the Kidneys when Using 213-Bi-DTPA-MAB.NIKULA T.; APOSTOLIDIS Christos; MOLINET Roger; CARLOS-MARQUEZ R.; BRANDES K.; SENEKOWITSCH-SCHMIDTKE R.Contributions to Conferences
1998Production of Ac-225 and Application of the Bi-213 Daughter in Cancer Therapy.KOCH Lothar; APOSTOLIDIS Christos; JANSSENS Willem; VAN GEEL Jacobus; MOLINET RogerContributions to Conferences
2005Production of Ac-225 from Th-229 for Targeted Alpha TherapyAPOSTOLIDIS CHRISTOS; MOLINET Roger; MORGENSTERN ALFREDArticles in Journals
2001Production of Carrier Free Actinium-225/Bismuth-212 from Thorium-229 for alpha-Immunitherapy.APOSTOLIDIS Christos; BETTI Maria; CARLOS-MARQUEZ R.; JANSSENS Willem; MOLINET Roger; NIKULA T.; QUADI AliContributions to Conferences
2001Radiopeptide Therapy with Cholecystokinin(CCK)-B/Gastrin Receptor Ligands Labeled with Auger/Conversion Electron-versus alpha- or Conventional beta Emitters.BEHR T.m.; BEHE M.; ANGERSTEIN C.; STABIN M.g.; APOSTOLIDIS Christos; MOLINET Roger; KOCH Lothar; ROESCH F.; BECKER W.Contributions to Conferences
2000Radiopeptide Therapy with Cholecystokinin-B/Gastrin Receptor Ligands: Dose-Limiting Toxicity and Therapeutic Efficacy of Auger / Conversion Electron (111-In, 140-Nd) vs alpha(213-Bi) or Conventional beta(90-Y, 153-Sm) Emitters.BEHR T.m.; BEBE M.; STABIN M.g.; ANGERSTEIN C.; MACH R.; HAGEMANN L.; APOSTOLIDIS Christos; MOLINET Roger; KOCH Lothar; ROESCH F., et alContributions to Conferences
2001Separation of 248Cm from a 252Cf Neutron Source for Production of Cm Targets.MALMBECK R.; APOSTOLIDIS Christos; CARLOS R.; GLATZ Jean paul; MOLINET Roger; MORGENSTERN A.; NICHOLL Adrian felim; PAGLIOSA G.; ROEMER K.; SCHAEDEL M., et alArticles in Journals
2002Single-Column Extraction Chromatographic Separation of U, Np, Pu and Am.MORGENSTERN A.; APOSTOLIDIS Christos; CARLOS-MARQUEZ R.; MAYER Klaus; MOLINET RogerArticles in Journals
2000Studies on the Red Marrow Dosimetry in Radioimmunotherapy. An Experimental Investigation of Factors Influencing the Radio-Induced Myelotoxicity in Therapy with beta-, Auger/Conversion Electron-, or alpha-Emitters.BEHR T.m.; SGOUROS G.; STABIN M.g.; BEHE M.; ANGERSTEIN Ch.; BLUMENTHAL R.d.; APOSTOLIDIS Christos; MOLINET Roger; SHARKEY R.m.; KOCH Lothar, et alArticles in Journals
2000Validation of 213Bi-alpha Radioimmunotherapy for Multiple Myeloma.COUTURIER O.; FAIVRE-CHAUVET A.; FILIPPOVICH I.v.; THEDREZ Ph.; SAI-MAUREL C.; BARDIES M.; MISHRA A.k.; GAUVRIT M.; BLAIN G.; APOSTOLIDIS Christos, et alArticles in Journals
Showing results 1 to 19 of 19

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top